You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 3, 2024

~ Buy the SYNRIBO Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SYNRIBO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Synribo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed Cephalon Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed ChemGenex Pharmaceuticals Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed Teva Branded Pharmaceutical Products R&D, Inc. Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00375219 ↗ Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation Completed Teva Branded Pharmaceutical Products, R&D Inc. Phase 2 2006-09-01 To evaluate the safety and efficacy of subcutaneous administration of omacetaxine mepesuccinate (HHT) in achieving a clinical response in CML patients in chronic, accelerated, or blast phase who have failed prior imatinib therapy and have the T315I kinase domain gene mutation.
NCT00462943 ↗ Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML Completed Cephalon Phase 2 2007-03-01 A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
NCT00462943 ↗ Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML Completed ChemGenex Pharmaceuticals Phase 2 2007-03-01 A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
NCT00462943 ↗ Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML Completed Teva Branded Pharmaceutical Products R&D, Inc. Phase 2 2007-03-01 A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Synribo

Condition Name

Condition Name for Synribo
Intervention Trials
Chronic Myeloid Leukemia 2
Leukemia 2
Refractory Myelodysplastic Syndrome 1
Acute Myelogenous Leukemia (AML) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Synribo
Intervention Trials
Leukemia, Myeloid 5
Leukemia 4
Preleukemia 4
Myelodysplastic Syndromes 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Synribo

Trials by Country

Trials by Country for Synribo
Location Trials
United States 21
France 2
India 2
Singapore 2
Canada 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Synribo
Location Trials
Texas 5
Pennsylvania 2
New York 2
Maryland 2
Indiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Synribo

Clinical Trial Phase

Clinical Trial Phase for Synribo
Clinical Trial Phase Trials
Phase 2 4
Phase 1/Phase 2 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Synribo
Clinical Trial Phase Trials
Completed 3
Terminated 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Synribo

Sponsor Name

Sponsor Name for Synribo
Sponsor Trials
M.D. Anderson Cancer Center 3
Teva Pharmaceuticals USA 3
Cephalon 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Synribo
Sponsor Trials
Industry 12
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.